← Leaderboards
David Y Liu
Protagonist Therapeutics, Inc.
$3,239,151
Attributed
$3,239,151
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2015–19$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,239,151 · 4
By mechanism
R44$2,796,377 · 2
R43$442,774 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Compliance Behavior”
- Constance Ann Benson · University Of California, San Diego$84,077,869
- Deborah J Donnell · Fred Hutchinson Cancer Center$72,420,612
- Norman Wolmark · Nsabp Foundation, Inc.$67,244,416
- Diane V Havlir · University Of California, San Francisco$47,697,266
- Stephen A Spector · University Of California, San Diego$40,696,057
- Robert Turner Schooley · University Of Colorado Denver$35,383,109
Research focus
Compliance BehaviorDrug CandidateDisulfidesDisease ModelSmall Business Innovation Research GrantIntestinesIn VivoSafetyLifeDoseDesignPeptidesPharmaceutical PreparationsScaffoldBaseReceptorAffectEngineeringPharmaceutical ChemistryAdverse EffectsBindingBlood CirculationCharacteristicsInnovation
Grant awards (6)
Developing the required biomarkers that define ferroportin target engagement and impact on downstream signaling for clinical translation$693,188
R44 · FY2019 · HL · contact PI
Developing the required biomarkers that define ferroportin target engagement and impact on downstream signaling for clinical translation$758,874
R44 · FY2018 · HL · contact PI
Developing the required biomarkers that define IL-23R target engagement and effect on downstream signaling for late stage drug development and early clinical proof-of-concept$373,781
R44 · FY2018 · DK · contact PI
Developing the required biomarkers that define IL-23R target engagement and effect on downstream signaling for late stage drug development and early clinical proof-of-concept$970,534
R44 · FY2017 · DK · contact PI
Hepcidin Mimetics for the Treatment of Iron Overload Diseases$218,828
R43 · FY2016 · HL · contact PI
Orally delivered antagonists of Interleukin-23 receptor for treatment of inflammatory bowel disease$223,946
R43 · FY2015 · DK · contact PI